title: Potential efficacy of citicoline as adjunct therapy in treatment of cerebral malaria.
abstract: Cerebral malaria (CM) is characterized by a dysregulated immune response that results in endothelial membrane destabilization and increased microparticle (MP) production. Citicoline (CTC) is a membrane stabilizer used for the treatment of neurological disorders. We evaluated the efficacy of CTC as adjunct therapy to aid recovery from experimental CM. We show that CTC reduces MP production in vitro; in combination with artesunate in vivo, confers partial protection against CM; and prolongs survival.
authors.affiliation: Vascular Immunology Unit, Medical Foundation Building, Department of Pathology, Sydney Medical School, The University of Sydney, Sydney, Australia.
authors.forename: Fatima
authors.initials: F
authors.lastname: El-Assaad
authors.forename: Valery
authors.initials: V
authors.lastname: Combes
authors.forename: Georges Emile Raymond
authors.initials: GE
authors.lastname: Grau
authors.forename: Ronan
authors.initials: R
authors.lastname: Jambou
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use; D000077332:Artesunate; D003566:Cytidine Diphosphate Choline / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016779:Malaria, Cerebral / Q000188:drug therapy*; D051379:Mice
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D003566:Cytidine Diphosphate Choline; D000077332:Artesunate